---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-022396"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T18:49:48.909900+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma FY2023 revenue falls 84% to $152K; net loss narrows to $10.9M

## Summary
- Revenue of $152,430 in FY2023, down from $969,783 in FY2022; net loss improved 31% to $10.9M.
- Operating expenses cut to $8.07M from $15.8M; cash and cash equivalents only $60K as of Dec 31, 2023.
- Entered global licensing agreement with AIBL for CNS drugs; received 23M AIBL shares valued at $10 per share.
- Regained Nasdaq compliance for $1.00 bid price and $2.5M stockholders' equity requirements in Aug/Sep 2023.
- Stockholders' equity of $8.39M at year-end; raised $1.75M via registered direct offering in July 2023.

## SEC filing metadata
- accession: 0001213900-24-022396
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024022396/0001213900-24-022396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024022396/ea0201766-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-022396
- JSON: https://secwatch.observer/filing/0001213900-24-022396.json
- Plain text: https://secwatch.observer/filing/0001213900-24-022396.txt

## Key facts
- Earnings Releases
  ABVC BIOPHARMA, INC. reported financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: reported results
  source text: ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390024022396/0001213900-24-022396-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.